Company Monitoring Page for Alexion

latest headlines for company on cafepharma

Alexion dumps ex-Achillion C3G program after seeing phase 2 data
Fierce Biotech
Thu, 07/30/20 - 11:01 am
Tags:
Alexion, Achillion, M&A, clinical trials
Biopharma takeovers show quantity, if not quality
EP Vantage
Mon, 07/13/20 - 11:13 am
Tags:
COVID-19, pandemic, M&A, Novo Nordisk, Corvidia, Gilead Sciences, Pionyr, Alexion, Portola Pharmaceuticals, Menarini, Stemline Therapeutics, Shionogi, Tetra Therapeutics
Genentech posts long-term data on near-approval Soliris rival
Fierce Biotech
Fri, 05/22/20 - 10:46 am
Tags:
Genentech, satralizumab, Soliris, Alexion, NMOSD
Martin Mackay’s rare disease startup gets $145 million as it enters the clinic
Endpoints
Tue, 05/19/20 - 10:42 am
Tags:
Martin Mackay, Alexion, rare disease, Rallybio, FNAIT
(Another) activist attack on Alexion, as Paul Singer-founded hedge fund calls for biotech to sell itself
Endpoints
Wed, 05/13/20 - 11:16 am
Tags:
Alexion, Paul Singer, activists
Alexion Pharma to Buy Portola for $18-Share, or $1.41 Billion
TheStreet.com
Tue, 05/5/20 - 11:08 am
Tags:
Alexion, M&A, Portola Pharmaceuticals, AndexXa
EMA gives thumbs up to key drugs from Novartis, Alexion, Vertex and more
Endpoints
Fri, 05/1/20 - 12:43 pm
Tags:
EMA, Europe, Novartis, Alexion, Vertex Pharmaceuticals
Alexion trials rare disease drug Ultomiris in severe COVID-19 cases
Pharmaforum
Tue, 04/21/20 - 12:28 pm
Tags:
Alexion, Ultomiris, COVID-19
Alexion to start Phase III study of blood disorder drug in Covid-19 respiratory disease
MedCity News
Mon, 04/20/20 - 10:40 am
Tags:
Alexion, COVID-19, Ultomiris, clinical trials
Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report
Fierce Pharma
Tue, 04/7/20 - 07:10 pm
Tags:
Alexion, COVID-19, clinical trials, Soliris
Who were biopharma's Q4 growth stars? Vertex, thanks to a new launch, plus Alexion, Regeneron and GSK
Fierce Pharma
Sat, 02/29/20 - 07:13 pm
Tags:
Vertex Pharmaceuticals, Alexion, Regeneron, GSK, earnings
One less rival for Immunovant, as Alexion abandons FcRn inhibitor
Endpoints
Wed, 02/26/20 - 10:36 am
Tags:
Alexion, anti-FcRn, Immunovant
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
Yahoo/Zacks.com
Thu, 01/16/20 - 10:14 am
Tags:
Alexion, ALS, Ultomiris, clinical trials
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
Yahoo/Benzinga
Sat, 01/11/20 - 11:02 pm
Tags:
JPMHC 2020, Bristol-Myers Squibb, Vertex Pharmaceuticals, Biomarin, Regeneron, Biogen, Alexion, Gilead Sciences, Amgen
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Fierce Pharma
Thu, 12/19/19 - 11:32 pm
Tags:
oncology, Rare Diseases, AstraZeneca, GSK, Alexion, Takeda, Soliris
Alexion shoots down 'proactive' sale demand from activist investor
Fierce Pharma
Fri, 12/6/19 - 10:42 am
Tags:
Alexion, investors, M&A
Roche's Chugai claims Alexion co-opted its patented tech in building Ultomiris
Fierce Pharma
Wed, 11/13/19 - 11:24 pm
Tags:
Alexion, Chugai, Roche, Ultomiris, patents
FDA approves Alexion's Ultomiris for another rare blood disease
Yahoo/Reuters
Sun, 10/20/19 - 05:31 pm
Tags:
Alexion, FDA, Ultomiris, aHUS
The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
Yahoo/Benzinga
Sun, 10/20/19 - 05:18 pm
Tags:
earnings, Eli Lilly, Alexion, Gilead Sciences, Biomarin, Edwards Lifesciences, Baxter International, Integra LifeSciences, Phathom Pharmaceuticals, IPOs, Foamix, Eton Pharmaceuticals, Melinta Therapeutics, Ligand Pharmaceuticals
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
Yahoo/Benzinga
Mon, 10/14/19 - 09:43 am
Tags:
JNJ, Flexion Therapeutics, Novartis, Amgen, Clearside Biomedical, Alexion, Assertio Therapeutics, Aldeyra Therapeutics, Lineage Therapeutics, IMMUTEP, Marinus Pharma

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.